Industries > Pharma > Global Cystic Fibrosis Therapeutics Market 2016-2026

Global Cystic Fibrosis Therapeutics Market 2016-2026

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies

PUBLISHED: 02 November 2016
PAGES: 191
PRODUCT CODE: PHA0151

Clear
WOOCS 2.2.1
SKU: PHA0151 Categories: , ,

The latest report from business intelligence provider Visiongain offers comprehensive analysis of the global cystic fibrosis market. Visiongain expects the global cystic fibrosis market to grow at a CAGR of 16.7% from 2016 to 2021. The global cystic fibrosis market is estimated to reach $7.7bn by 2021.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this 191-page report you will receive 113 tables, charts and graphs – all unavailable elsewhere.

The 191 page report provides clear detailed insight into the global cystic fibrosis market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Global Cystic Fibrosis Therapeutics Market 2016-2026

Report Scope

Global Cystic Fibrosis market forecasts from 2016-2026

• Cystic Fibrosis submarket forecasts from 2016-2026 covering:
– Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
– Protein Transcription Modulators
– Pancreatic Enzyme Products (PEP)
– Other therapies

Individual drug revenue forecasts from 2016-2026 by pharmacological classes:

– Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators:
• Orkambi
• Kalydeco
• VX-661 + ivacaftor
• Second corrector/VX-661/ivacaftor

– Protein Transcription Modulators
• Pulmozyme
• QR-010
• Translarna

– Pancreatic Enzyme Products (PEP)
• Ceron

– Other therapies
• Cayston
• TOBI

• Revenue forecasts from 2016-2026 and discussion of relevant trends and developments in the leading national cystic fibrosis market

• Analysis of the key factors driving growth in the global, regional and country level of the Cystic Fibrosis Market from 2016-2026

Patent and clinical trials information of the marketed and pipeline products for cystic fibrosis

• The dynamic of pricing, patient share and market share of the leading cystic fibrosis drugs in the US and Europe

• Discussion on selected leading companies marketing and developing cystic fibrosis drugs:
– Vertex Pharmaceuticals
– Roche
– AbbVie
– Gilead Sciences
– Novartis

Visiongain’s study is intended for anyone requiring commercial analyses for the Cystic Fibrosis Market and leading companies. You find data, trends and predictions.

Buy our report today: Global Cystic Fibrosis Therapeutics Market 2016-2026: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Cystic Fibrosis Therapeutics Market 2016-2026


Download sample pages

Complete the form below to download your free sample pages for Global Cystic Fibrosis Therapeutics Market 2016-2026


Latest Pharma news

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

READ

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

READ

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.

01 April 2021

READ

Visiongain Publishes Inhalation & Nasal Spray Generic Drugs Market Report 2021-2031

Rising prevalence of chronic respiratory diseases including asthma, COPD, and allergic rhinitis; rising geriatric population, escalating investment in drug R&D by biopharmaceutical & pharmaceutical companies; growing respiratory health care awareness; and new product launches worldwide are some of the major factors that boosting the growth of global inhalation & nasal spray generic drugs market.

31 March 2021

READ

Categories